Oral antidiabetic agents. A guide to selection

Drugs

Volumn 55, Issue 2, 1998, Pages 225-236

  Scheen, André J ^a,b   Lefebvre, Pierre J ^a  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLUCOSE; INSULIN; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

BLOOD GLUCOSE MONITORING; CARBOHYDRATE ABSORPTION; DISEASE SEVERITY; DRUG CHOICE; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LACTIC ACIDOSIS; LIPID METABOLISM; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; REVIEW; RISK;

ADMINISTRATION, ORAL; AGED; ALPHA-GLUCOSIDASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLES;

EID: 0031939899     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855020-00004     Document Type: Review

References (81)

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-97
2. Scheen AJ, Lefebvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology: oral antidiabetics. Berlin: Springer Verlag, 1995: 7-42
3. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 836-48
4. Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology: oral antidiabetics. Berlin: Springer Verlag, 1995
5. Melander A. Oral antidiabetic drugs: an overview. Diabetic Med 1996; 13 Suppl. 6: S143-7
6. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997; 54: 355-68
7. Lefebvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs 1992; 44 Suppl. 3: 29-38
8. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1995; 343: 95-100
9. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabetic Med 1988; 5: 275-81
10. Alberti KGMM, Gries FA, Jervell J, et al. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabetic Med 1994; 11: 899-909
11. American Diabetes Association. Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-8
12. Riddle MC. Tactics for type II diabetes. Endocrinol Metab Clin North Am 1997; 26: 659-77
13. Melander A, Bitzen P-O, Faber O, et al. Sulphonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58-72
14. Groop LC. Sulfonylureas and NIDDM. Diabetes Care 1992; 15: 737-54
15. Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. Chichester: J. Wiley, 1992: 745-72
16. Campbell IW. Hypoglycemia and type II diabetes: sulfonylureas. In: Frier B, Fisher M, editors. Hypoglycemia and diabetes: clinical and physiological aspects. London: Edward Arnold, 1993: 387-92
17. Asplund K, Wiholm B-E, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983; 24: 412-7
18. Stahl M, Berger W. Sulfonylurées: pharmacologie et risque hypoglycémique. In: Journées de diabétologie de l'Hôtel-Dieu. Paris: Flammarion Médecine-Sciences, 1995: 108-19
19. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study Group (UKPDS) 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ 1995; 310: 83-8
20. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
21. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
22. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. Chichester: J. Wiley, 1992: 773-95
23. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49
24. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9
25. Andreani D, Lefebvre P, editors. Metformin: mechanisms of action and clinical use. Diabetes Metab Rev 1995; 11 Suppl. 1: S1-108
26. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99-110
27. Scheen AJ, Lefebvre PJ. Pharmacological treatment of the obese diabetic patient. Diabete Metab 1993; 19: 547-59
28. Lefebvre PJ, Scheen AJ. Improving the action of insulin. Clin Invest Med 1995; 18: 340-7
29. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996; 19: 920-6
30. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-9
31. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30: 187-228
32. Morley JE, Perry HM. The management of diabetes mellitus in older individuals. Drugs 1991; 41: 548-65
33. Scheen AJ. Non-insulin-dependent diabetes mellitus in the elderly. Baillières Clin Endocrinol Metab. 1997; 11: 388-406
34. Lebovitz HE. Oral antidiabetic drugs: the emergence of alpha glucosidase inhibitors. Drugs 1992; 44 Suppl. 3: 21-8
35. Lefebvre PJ, Standl E, editors. New aspects in diabetes: treatment strategies with alpha-glucosidase inhibitors. Berlin-New York: de Gruyter, 1992
36. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-54
37. Nieuwenhuijzen Kruseman AC, Sels JPJE, Wolffenbuttel BHR, editors. α-Glucosidase inhibitors in diabetes. Eur J Clin Invest 1994; 24Suppl. 3: 1-54
38. Meng-Hee Tan. α-Glucosidase inhibitors in the treatment of diabetes. Curr Opin Endocrinol Diab 1997; 4: 48-55
39. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-8
40. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9
41. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997; 26: 553-73
42. Kaneko T. Troglitazone (CS-045): a new antidiabetic agent. Horm Metab Res 1997; 29: 203-13
43. Spencer CM, Markham A. Troglitazone. Drugs 1997; 54: 89-101
44. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-93
45. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-9
46. Mimura K, Umeda F, Hiramatsu S, et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med 1994; 11: 685-91
47. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-9
48. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-8
49. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-301
50. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev 1994; 10: 31-43
51. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of troglitazone and metformin in NIDDM [abstract]. Diabetes 1997; 46 Suppl. 1: 34A
52. Hermann LS, Scherstén B, Bitzén P-O, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994; 17: 1100-9
53. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the Essen study. Diabetes Care 1994; 17: 561-6
54. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in NIDDM patients with diet failure [abstract]. Diabetologia 1996; 39 Suppl. 1: A230
55. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res 1985; 15 Suppl.: 105-11
56. Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides? Horm Metabol Res 1985; 15 Suppl. 1: 111-5
57. FDA strengthens warnings for diabetes drug. Infobeat stories [online]: [1 page], 1997 1 Dec. Available from: URL: http://www.infobeat.com/stories/cgi/story.cgi.?id+6243612-bf7
58. Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents: drug interactions of clinical importance. Drug Saf 1995; 12: 32-45
59. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994; 17: 1542-4
60. Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990; 13 Suppl 3.: 37-41
61. Johansen K. Acarbose treatment of sulfonylurea-treated non-insulin-dependent diabetics. Diab Metab 1990; 10: 219-33
62. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35
63. Holman RR, Cull CA, Turner RC. Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients [abstract]. Diabetologia 1996; 39 Suppl. 1: A44
64. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjunct therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996; 19: 252-4
65. Hanefeld M, Bär K, Mertes G, Berlinghoff R. Metformin improves metabolic control in non-insulin-dependent diabetics with acarbose monotherapy [abstract]. Diabetologia 1997; 40 Suppl. 1: A312
66. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, et al. Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24 Suppl. 3: 50-4
67. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Med 1996; 13: 365-70
68. Scheen AJ, Castillo MJ, Lefebvre PJ. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta Clin Belg 1993; 48: 259-68
69. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-64
70. Scheen AJ, Lefebvre PJ. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract 1989; 6: S33-43
71. Castillo M, Scheen AJ, Paolisso G, et al. The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol 1987; 116: 364-72
72. Golay A, Guillet-Dauphiné N, Fendel A, et al. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 1995; 11 Suppl. 1: S63-7
73. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvements in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-12
74. Hotta N, Kakuta H, Koh N, et al. The effects of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabetic Med 1993; 10: 355-8
75. Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-32
76. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-71
77. Knight PV, Semple CG, Kesson CM. The use of metformin in the older patient. J Clin Exp Gerontol 1986; 8: 51-8
78. Chalmers J, McBain AM, Brown IRF, et al. Metformin: is its use contraindicated in the elderly? Pract Diabetes 1992; 9: 51-3
79. Gregorio F, Ambrosi F, Filipponi P, et al. Is metformin safe enough for ageing type 2 diabetic patients? Diab Metab 1996; 22: 43-50
80. Lalau JD, Vermersch A, Hary L, et al. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990; 28: 329-32
81. Turner R, Cull C, Holman R, for the United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-45